<SEC-DOCUMENT>0001193125-24-182547.txt : 20240723
<SEC-HEADER>0001193125-24-182547.hdr.sgml : 20240723
<ACCEPTANCE-DATETIME>20240723060650
ACCESSION NUMBER:		0001193125-24-182547
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20240722
FILED AS OF DATE:		20240723
DATE AS OF CHANGE:		20240723

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IMMUTEP Ltd
		CENTRAL INDEX KEY:			0001506184
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35428
		FILM NUMBER:		241132846

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 32, SUITE 32.07 AUSTRALIA SQUARE
		STREET 2:		264 GEORGE STREET
		CITY:			SYDNEY,
		STATE:			C3
		ZIP:			NSW 2000
		BUSINESS PHONE:		612 8315 7003

	MAIL ADDRESS:	
		STREET 1:		LEVEL 32, SUITE 32.07 AUSTRALIA SQUARE
		STREET 2:		264 GEORGE STREET
		CITY:			SYDNEY,
		STATE:			C3
		ZIP:			NSW 2000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Prima BioMed Ltd
		DATE OF NAME CHANGE:	20101119
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d871145d6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML><HEAD>
<TITLE>6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 6-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Date as July 22, 2024 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number 001-35428 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>IMMUTEP
LIMITED </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name as Specified in its Charter) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of
Registrant&#146;s Name) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Level 32, Australia Square </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>264 George Street, Sydney </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NSW 2000, Australia </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form 20-F&#8194;&#9746;&#8195;&#8195;&#8195;Form
40-F&#8194;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule
101(b)(1):&#8194;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule
101(b)(7):&#8194;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing
the information to the Commission pursuant to Rule&nbsp;12g3-2(b) under the Securities Exchange Act of 1934. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yes&#8194;&#9744;&#8195;&#8195;&#8195;No&#8194;&#9746; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If &#147;Yes&#148; is marked, indicated below the file number assigned to the registrant in connection with Rule 12g3-2(b): Not applicable. </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Exhibit</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description&nbsp;of&nbsp;Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">99.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><A HREF="d871145dex991.htm">Immutep Announces Successful Meeting with FDA on Phase III Design in Non-Small Cell Lung Cancer</A></P></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: July 22, 2024 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">IMMUTEP LIMITED</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Marc Voigt</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Marc Voigt</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d871145dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g871145g46n03.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ASX/Media Release </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep Announces Successful Meeting with FDA on Phase III Design </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>in <FONT STYLE="white-space:nowrap">Non-Small</FONT> Cell Lung Cancer </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Final discussion with the FDA, successfully concluding the regulatory preparations for the <FONT
STYLE="white-space:nowrap">TACTI-004</FONT> Phase III trial design to evaluate efti in combination with KEYTRUDA</I><I><SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP></I><I> (pembrolizumab), MSD&#146;s <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> therapy, and standard chemotherapy in first-line <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer</I> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I><FONT STYLE="white-space:nowrap">TACTI-004</FONT> registrational trial will enrol ~750 patients regardless of <FONT
STYLE="white-space:nowrap">PD-L1</FONT> expression in order to address the entire 1L NSCLC market eligible for <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> therapy</I> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SYDNEY, AUSTRALIA &#150; 22</B><B></B><B>&nbsp;July </B><B>2024 &#150;</B> <U>Immutep Limited</U> (ASX: IMM; NASDAQ: IMMP) (&#147;Immutep&#148; or
&#147;the Company&#148;), a clinical-stage biotechnology company developing novel <FONT STYLE="white-space:nowrap">LAG-3</FONT> immunotherapies for cancer and autoimmune disease, today announces that positive feedback has been received from the US
Food and Drug Administration (&#147;FDA&#148;) regarding the planned <FONT STYLE="white-space:nowrap">TACTI-004</FONT> Phase III trial of eftilagimod alfa (&#147;efti&#148;) in combination with
KEYTRUDA<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> (pembrolizumab), MSD&#146;s <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> therapy, and histology-based platinum doublet chemotherapy for
the treatment of first-line metastatic <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer (1L NSCLC), regardless of <FONT STYLE="white-space:nowrap">PD-L1</FONT> expression. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA feedback from this Type C meeting, along with feedback previously received from the Paul-Ehrlich-Institut (&#147;PEI&#148;) and the Spanish Agency for
Medicines and Health Products (&#147;AEMPS&#148;), concludes the preparatory regulatory interactions for the design of this registrational trial. This marks a significant step forward to develop an effective treatment for <FONT
STYLE="white-space:nowrap">non-squamous</FONT> and squamous 1L NSCLC patients who have high, low, or no <FONT STYLE="white-space:nowrap">PD-L1</FONT> expression and are eligible for
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> therapy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The <FONT STYLE="white-space:nowrap">TACTI-004</FONT>
Phase III trial, which will enrol ~750 patients, is based on the positive efficacy and safety data in 1L NSCLC generated from the <FONT STYLE="white-space:nowrap">TACTI-002</FONT> Phase II and <FONT STYLE="white-space:nowrap">INSIGHT-003</FONT>
trials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;We are pleased with the FDA&#146;s feedback as this allows us to successfully conclude our regulatory preparation for the <FONT
STYLE="white-space:nowrap">TACTI-004</FONT> registrational trial. This represents a key milestone in our late-stage development process for efti centred on potentially driving a new standard of care globally in the treatment of <FONT
STYLE="white-space:nowrap">non-small</FONT> cell lung cancer. We hope to achieve this through efti in combination with KEYTRUDA, which has led to strong efficacy data with a favourable safety profile in 1L NSCLC patients regardless of <FONT
STYLE="white-space:nowrap">PD-L1</FONT> expression,&#148; stated Christian&nbsp;Mueller, Immutep&#146;s SVP, Regulatory and Strategy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">KEYTRUDA<SUP
STYLE="font-size:75%; vertical-align:top">&reg;</SUP> is a registered trademark of Merck Sharp&nbsp;&amp; Dohme LLC, a subsidiary of Merck&nbsp;&amp; Co., Inc., Rahway, NJ, USA. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">TACTI-004</FONT> (Two ACTive <FONT STYLE="white-space:nowrap">Immunotherapies-004)</FONT> Registrational Phase III Trial
Design </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">TACTI-004</FONT> will be a 1:1 randomized, double-blind, multinational, controlled clinical trial to evaluate
Immutep&#146;s efti in combination with KEYTRUDA and standard chemotherapy compared to the <FONT STYLE="white-space:nowrap">standard-of-care,</FONT> KEYTRUDA in combination with chemotherapy and placebo in first-line metastatic <FONT
STYLE="white-space:nowrap">non-small</FONT> cell lung cancer (NSCLC), regardless of <FONT STYLE="white-space:nowrap">PD-L1</FONT> expression. In this pivotal <FONT STYLE="white-space:nowrap">PD-L1</FONT> all comer trial, the dual primary endpoints
will be progression-free and overall survival with a prespecified futility boundary and a <FONT STYLE="white-space:nowrap">pre-planned</FONT> interim analysis. The trial will be conducted globally and enrol approximately 750 NSCLC patients
(including both squamous and <FONT STYLE="white-space:nowrap">non-squamous</FONT> subtypes). </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g871145g46n03.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Eftilagimod Alfa (Efti) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Efti is Immutep&#146;s proprietary soluble <FONT STYLE="white-space:nowrap">LAG-3</FONT> protein and MHC Class&nbsp;II agonist that stimulates both innate and
adaptive immunity for the treatment of cancer. As a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> antigen presenting cell (APC) activator, efti binds to MHC (major histocompatibility complex)
Class&nbsp;II molecules on APC leading to activation and proliferation of CD8+ cytotoxic T cells, CD4+ helper T cells, dendritic cells, NK cells, and monocytes. It also upregulates the expression of key biological molecules like <FONT
STYLE="white-space:nowrap">IFN-&#436;</FONT> and CXCL10 that further boost the immune system&#146;s ability to fight cancer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Efti is under evaluation for
a variety of solid tumours including <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), and metastatic breast cancer. Its favourable safety profile enables various combinations,
including with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-[L]1</FONT></FONT> immunotherapy and/or chemotherapy. Efti has received Fast Track designation in first line HNSCC and in first line NSCLC from the United
States Food and Drug Administration (FDA). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Immutep </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep is a clinical-stage biotechnology company developing novel <FONT STYLE="white-space:nowrap">LAG-3</FONT> immunotherapy for cancer and autoimmune
disease. We are pioneers in the understanding and advancement of therapeutics related to Lymphocyte Activation <FONT STYLE="white-space:nowrap">Gene-3</FONT> <FONT STYLE="white-space:nowrap">(LAG-3),</FONT> and our diversified product portfolio
harnesses its unique ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information,
please visit <U>www.immutep.com</U>. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Australian Investors/Media: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Catherine Strong, Morrow Sodali </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+61 (0)406 759 268;
<U>c.strong@morrowsodali.com</U> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>U.S. Investors/Media: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chris Basta, VP, Investor Relations and Corporate Communications </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1 (631) 318 4000; <U>chris.basta@immutep.com</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This
announcement was authorised for release by the CEO of Immutep Limited. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep Limited</B>, Level&nbsp;32, Australia Square, 264 George
Street, Sydney NSW 2000, Australia </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ABN: 90 009 237 889 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g871145g46n03.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g871145g46n03.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M-.SO[6_B\VUF61.AQV^H[52:>QK&<9J\2S3*"@ H * "@ H * "@ H * "@
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MT:<7"[1S4D:Z7XM$<'RK'<+M'H#CC\C6?PST.1Q4*MD:?Q+_ .0/9_\ 7?\
M]E-=)ZAK>!_^10L?^!_^AF@#B?B)_P C.O\ UP7^9H Z[Q__ ,BG)_UT3^=
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M#U&@ H * "@ H * (+RW%W9S6Q8J)4*$CMD4-75B9+F5C-T70$T5YBD[2^8
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M1Q]EDCW$?B"* .A\->&E\.031K=/.9B"Q*[0,>@_&@"+7?!NGZY.;EF>"Y(
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M,$T,J$I*VX\X(.,<>E #I;)9)3,DCQ2$!69#]X#H#GZF@!PM(DMDMU7;&I!
MSW!S_.@![PJ\T<ISN0$#\<9_E0!";!/*5$=X]LC2AE(R&8DGK_O&@!XM0?*+
MNTC1$E6;&>1CG'UH B_LRV,4<,B;X8V++&W*CVQZ#/ [4 +_ &;;+&8DC"1&
M19-BC !&#T_ 4 6B@*[>E "1QB*)(U^ZBA1^% &'8>#]+T[4DO[=91.A)&Y\
MCD$'C\30!OT % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
: % !0 4 % !0 4 % !0 4 % !0 4 % '_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
